以2种相关的冠状病毒中的一种重要本科的晶体结构为指导,德国科学家宣称,已确定这是一个有希望的的出发点来设计一种治疗SARS的新药物。许多病毒,包括引起SARS的冠状病毒,是靠一种主要的蛋白酶活化进行复制的。病毒只有大量复制才会引发症状,因此控制这种酶是开发新药的主要目标。 Guided by the crystal structure of one of two major associated coronaviruses, German scientists claim that it has been determined that this is a promising starting point for the design of a new drug for the treatment of SARS. Many viruses, including the SARS-causing coronavirus, are replicated by a major protease activation. Viruses trigger symptoms only when they are replicated in large quantities, so controlling this enzyme is the main goal of developing new drugs.